search
Back to results

TAS-102 in Extrapulmonary Neuroendocrine Carcinoma (TAS-102 NEC)

Primary Purpose

High-grade Extra Pulmonary Neuroendocrine Cancer

Status
Unknown status
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
All patients- TAS-102
Sponsored by
Baylor Research Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for High-grade Extra Pulmonary Neuroendocrine Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Pathologic confirmation of high grade NEC using WHO criteria as determined by Ki67>20%, poorly differentiated (G3) characteristics, or >20 mitotic figures/10 high-power fields.
  • Unknown primary may be included. Suspected extrapulmonary patients with known lung primary will be excluded.
  • Prior treatment with a platinum containing regimen
  • RECIST 1.1 measurable disease
  • Evidence of stage IV, metastatic disease
  • Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2.
  • Serum albumin ≥2.5 gm/dL.
  • Expected survival ≥3 months.
  • Adequate hematologic function as defined by: a) Absolute neutrophil count (ANC) >1500/mm3; b) Platelets ≥75,000/mm3; c) Hemoglobin >8 g/dL (in the absence of red blood transfusion).
  • Adequate liver function, as defined by: a) Serum total bilirubin ≤2.5 x ULN mg/dL. b) ALT (SGPT) and AST (SGOT) ≤5 x upper limit of normal (ULN).
  • Adequate renal function, as defined by serum creatinine ≤2.0 x ULN, or creatinine clearance ≥30 mL/min
  • Females of child bearing potential must agree to use contraception to avoid pregnancy throughout the study.

Exclusion Criteria:

  • Women who are pregnant or breastfeeding.
  • Evidence of low-grade or well-differentiated features as determined by the investigator.
  • Functional neuroendocrine tumors are excluded.
  • Known pulmonary primary or small cell lung cancer will be excluded.
  • Significant or uncontrolled congestive heart failure (CHF), myocardial infarction or significant ventricular arrhythmias within the last six months.
  • Active infection or antibiotics within 48 hours prior to study enrollment, including unexplained fever (temp > 38°C).
  • Other severe and/or uncontrolled medical conditions or other conditions that could affect their participation such as: a) Severe impaired lung functions as defined by spirometry and DLCO that is 50% of the normal predicted value and/or O2 saturation that is 88% or less at rest on room air, b) Uncontrolled diabetes,c) Liver disease such as cirrhosis or severe hepatic impairment, d) Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the integrity of the study.
  • Taking other investigational or anti-cancer treatments while participating in this study. Concurrent radiotherapy is allowed provided to non-target lesions. If target lesions have received radiation therapy, progression must have been demonstrated prior to enrollment.
  • Prior or concurrent malignancy, except for the following: a) Adequately treated basal cell or squamous cell skin cancer; b) Cervical carcinoma in situ; c) Adequately treated Stage I or II cancer from which the subject is currently in complete remission; d) Or any other cancer from which the subject has been disease-free for 3 years.

Sites / Locations

  • Baylor Scott and White University Medical Center,Recruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

TAS-102

Arm Description

Patients will receive TAS-102, Orally, BID for 5 days a week with 2 days rest for 14 days, followed by a 14-day rest treatment cycle. Treatment may continue until disease progresses, intolerable toxicity is developed, or if the patient becomes pregnant or dies.

Outcomes

Primary Outcome Measures

Overall Response Rate (ORR)
To assess clinical activity [ORR = Partial response (PR)+Complete response (CR) ] of TAS-102 in patients with metastatic, extra pulmonary high grade NEC

Secondary Outcome Measures

Overall Survival (OS)
To assess OS in patients with metastatic extra pulmonary high grade NEC who received TAS-102 In comparison with historical records.
Progression free survival (PFS)
To assess PFS in patients with metastatic extra pulmonary high grade NEC who received TAS-102 in comparison with historical records

Full Information

First Posted
July 31, 2019
Last Updated
January 16, 2020
Sponsor
Baylor Research Institute
Collaborators
Taiho Oncology, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04042714
Brief Title
TAS-102 in Extrapulmonary Neuroendocrine Carcinoma
Acronym
TAS-102 NEC
Official Title
An Open-label, Phase II Investigation of TAS-102 in Patients With High Grade, Extrapulmonary Neuroendocrine Carcinoma
Study Type
Interventional

2. Study Status

Record Verification Date
January 2020
Overall Recruitment Status
Unknown status
Study Start Date
August 15, 2019 (Actual)
Primary Completion Date
August 15, 2023 (Anticipated)
Study Completion Date
August 15, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Baylor Research Institute
Collaborators
Taiho Oncology, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to test the safety and efficacy of drug, TAS-102 (trifluridine/tipiracil), in patients with extrapulmonary (outside the lung) high-grade neuroendocrine cancer. TAS-102 demonstrated improved survival and tolerability in patients with colorectal cancer and is currently approved by the FDA and marketed under the brand name Lonsurf for the treatment of patients with metastatic colorectal cancer (mCRC). Recently, a study evaluating TAS-102 showed a case of complete remission of high-grade NEC. Given the safety profile of TAS-102 and the remarkable single agent activity in a disease with otherwise dismal outcomes, we hope that TAS-102 may show tolerability and efficacy in neuro-endocrine cancer and propose further exploration in patients with extrapulmonary (outside the lung) high-grade neuroendocrine cancer.
Detailed Description
Neuroendocrine tumors are highly prevalent cancer showing heterogeneous array of behaviors. For intermediate/high grade and poorly differentiated neuroendocrine carcinomas (NEC) that occur outside the lung, there is no acceptable standard of care. Most patients are treated with a platinum-based chemotherapy in the front-line setting and evidence for therapies in the second line setting is minimal representing a significant unmet need. However, the response rates have been unsatisfactory with progression-free survival of only 2.3 to 6.2 months, and there is an unmet need for an effective treatment for patients with refractory disease. TAS-102 is a novel combination medicinal product consisting of a thymidine-based nucleoside analogue (trifluridine; FTD) as the active component and the thymidine phosphorylase inhibitor tipiracil hydrochloride (TPI) that has shown promising activity in phase I trials in patients with solid tumors and phase II in patients with gastric cancer. FTD enters cancer cells, interferes with DNA synthesis, inhibits cell proliferation and inhibit tumor growth. TPI helps FTD sustain its level in cells without degradation by thymidine phosphorylase (Tpase).Thus TAS-102 uses dual approach to inhibit rapid degradation of trifluridine and subsequent tumor growth. Given the safety profile and efficacy, the study is designed to explore/evaluate efficacy of TAS-102 and identify characteristics of patients who may respond to this treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
High-grade Extra Pulmonary Neuroendocrine Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Model Description
Patients with metastatic high-grade extra pulmonary NEC, who failed front line treatment with a platinum containing regimen, who meets the enrollment criteria will receive TAS-102 as a single agent until either progression or unacceptable toxicity.
Masking
None (Open Label)
Allocation
N/A
Enrollment
14 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
TAS-102
Arm Type
Experimental
Arm Description
Patients will receive TAS-102, Orally, BID for 5 days a week with 2 days rest for 14 days, followed by a 14-day rest treatment cycle. Treatment may continue until disease progresses, intolerable toxicity is developed, or if the patient becomes pregnant or dies.
Intervention Type
Drug
Intervention Name(s)
All patients- TAS-102
Other Intervention Name(s)
Trifluridine, Tipiracil
Intervention Description
Patients will receive TAS-102, Orally, BID for 5 days a week with 2 days rest for 14 days, followed by a 14-day rest treatment cycle. Treatment may continue until disease progresses, intolerable toxicity is developed, or if the patient becomes pregnant or dies.
Primary Outcome Measure Information:
Title
Overall Response Rate (ORR)
Description
To assess clinical activity [ORR = Partial response (PR)+Complete response (CR) ] of TAS-102 in patients with metastatic, extra pulmonary high grade NEC
Time Frame
24 months
Secondary Outcome Measure Information:
Title
Overall Survival (OS)
Description
To assess OS in patients with metastatic extra pulmonary high grade NEC who received TAS-102 In comparison with historical records.
Time Frame
24 months
Title
Progression free survival (PFS)
Description
To assess PFS in patients with metastatic extra pulmonary high grade NEC who received TAS-102 in comparison with historical records
Time Frame
24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Pathologic confirmation of high grade NEC using WHO criteria as determined by Ki67>20%, poorly differentiated (G3) characteristics, or >20 mitotic figures/10 high-power fields. Unknown primary may be included. Suspected extrapulmonary patients with known lung primary will be excluded. Prior treatment with a platinum containing regimen RECIST 1.1 measurable disease Evidence of stage IV, metastatic disease Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2. Serum albumin ≥2.5 gm/dL. Expected survival ≥3 months. Adequate hematologic function as defined by: a) Absolute neutrophil count (ANC) >1500/mm3; b) Platelets ≥75,000/mm3; c) Hemoglobin >8 g/dL (in the absence of red blood transfusion). Adequate liver function, as defined by: a) Serum total bilirubin ≤2.5 x ULN mg/dL. b) ALT (SGPT) and AST (SGOT) ≤5 x upper limit of normal (ULN). Adequate renal function, as defined by serum creatinine ≤2.0 x ULN, or creatinine clearance ≥30 mL/min Females of child bearing potential must agree to use contraception to avoid pregnancy throughout the study. Exclusion Criteria: Women who are pregnant or breastfeeding. Evidence of low-grade or well-differentiated features as determined by the investigator. Functional neuroendocrine tumors are excluded. Known pulmonary primary or small cell lung cancer will be excluded. Significant or uncontrolled congestive heart failure (CHF), myocardial infarction or significant ventricular arrhythmias within the last six months. Active infection or antibiotics within 48 hours prior to study enrollment, including unexplained fever (temp > 38°C). Other severe and/or uncontrolled medical conditions or other conditions that could affect their participation such as: a) Severe impaired lung functions as defined by spirometry and DLCO that is 50% of the normal predicted value and/or O2 saturation that is 88% or less at rest on room air, b) Uncontrolled diabetes,c) Liver disease such as cirrhosis or severe hepatic impairment, d) Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the integrity of the study. Taking other investigational or anti-cancer treatments while participating in this study. Concurrent radiotherapy is allowed provided to non-target lesions. If target lesions have received radiation therapy, progression must have been demonstrated prior to enrollment. Prior or concurrent malignancy, except for the following: a) Adequately treated basal cell or squamous cell skin cancer; b) Cervical carcinoma in situ; c) Adequately treated Stage I or II cancer from which the subject is currently in complete remission; d) Or any other cancer from which the subject has been disease-free for 3 years.
Facility Information:
Facility Name
Baylor Scott and White University Medical Center,
City
Dallas
State/Province
Texas
ZIP/Postal Code
75246
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Preethi Ravindranathan, MS
Phone
214-820-8685
Email
preethi.ravindranathan@bswhealth.org
First Name & Middle Initial & Last Name & Degree
Silviya Meletath, MBBS
Phone
214-820-4987
Email
Silviya.Meletath@BSWHealth.org
First Name & Middle Initial & Last Name & Degree
Scott Paulson, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

TAS-102 in Extrapulmonary Neuroendocrine Carcinoma

We'll reach out to this number within 24 hrs